Company Overview and News

 
Trai seeks views on charges for accessing submarine cable bandwidth

2018-10-19 financialexpress
Telecom regulator Trai Thursday launched the consultation process to determine charges for accessing submarine cable bandwidth vital for linking domestic telecom networks with global networks.
532454 TATACOMM BHRQY BHARTIARTL 500483

 
Tata Communications Limited - Press Release

2018-10-19 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
TATACOMM 500483

 
Tata Communications Limited - Press Release

2018-10-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
TATACOMM 500483

 
Tata Communications Limited - Press Release

2018-10-09 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
TATACOMM 500483

 
Tata Communications buys Netherlands-based IoT firm Teleena

2018-10-04 freepressjournal.in
New Delhi: Tata Communications on Wednesday announced it has acquired 100 per cent stake in the Netherlands-based mobility and internet-of-things specialist firm Teleena.”Tata Communications is the sole shareholder (in Teleena). We now own 100 per cent of Teleena,” Anthony Bartolo, chief product officer, Tata Communications, said. This acquisition follows Tata Communications’ investment in Teleena in January 2017, when the company became the single largest shareholder in Teleena with a 35 per cent stake.
TATACOMM 500483

 
Tata Comm subsidiary acquires Netherlands-based Teleena

2018-10-03 financialexpress
Tata Communications (Netherlands), a wholly-owned indirect subsidiary of Tata Communications, on Wednesday said it has acquired the balance 65% stake in Teleena Holding, a mobile virtual network enabler headquartered in the Netherlands. With this Tata Communications’ stake in Teleena goes up to 100%. However, the company did not disclose the price at which it acquired the 65% stake. Teleena’s technology reduces the operational complexity and cost of mobility and Internet of Things (IoT) deployments for businesses.
TATACOMM 500483

 
Tata Comm fully acquires Netherlands-based IoT firm Teleena

2018-10-03 moneycontrol
Tata Communications announced it has acquired 100 percent stake in the Netherlands-based mobility and internet-of-things specialist firm Teleena.
TATACOMM 500483

 
Tata Communications acquires Internet of Things firm Teleena

2018-10-03 financialexpress
Tata Communications, a leading global digital infrastructure provider, on Wednesday said it was acquiring Teleena, a Netherlands-based Internet of Things (IoT) connectivity specialist and mobile virtual network enabler (MVNE).
TATACOMM 500483

13
XentIT Teams with Trend Micro and Qualys to Offer New Healthcare Cloud Security Stack for Microsoft Azure

2018-09-27 accesswire
CROFTON, MD / ACCESSWIRE / September 27, 2018 / XentIT today announced its cloud security offering in partnership with Trend Micro and Qualys, the Healthcare Cloud Security Stack (HCSS) for Microsoft Azure. The solution provides a unified dashboard that combines vulnerability information from Qualys and the appropriate protection capabilities from Trend Micro. Combining the implementation and management capabilities of XentIT with the unified dashboard for vulnerability detection and response, this new offering allows healthcare entities to build security into their data-driven healthcare decision-making applications as they migrate workloads to the cloud.
TMICF HCTHY TATACOMM DTEGF CTSH 4704 HCLTECH QLYS TMICY 532281 DXC.WI MSFT DXC 500483 DTEGY

 
Tata Communications Limited - Press Release

2018-09-27 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
TATACOMM 500483

 
Tata Communications Limited - Reply to Clarification Sought

2018-09-24 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
TATACOMM 500483

 
Tata Communications Limited - Clarification

2018-09-19 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
TATACOMM 500483

 
Tata Communications: Now sole Indian on the Formula 1 grid

2018-09-17 moneycontrol
The split second decisions that reigning world champions Mercedes take during a race are a result of real time data provided by Tata Communications, Formula 1's connectivity partner since 2012 and now the only Indian presence in the paddock.
TATACOMM 500483

 
Tata Communications Limited - Press Release

2018-09-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
TATACOMM 500483

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...